Abstract
In adult mammalian brain, occurrence of the synthesis of estradiol from endogenous cholesterol has been doubted because of the inability to detect dehydroepiandrosterone synthase, P45017α. In adult male rat hippocampal formation, significant localization was demonstrated for both cytochromes P45017α and P450 aromatase, in pyramidal neurons in the CA1–CA3 regions, as well as in the granule cells in the dentate gyrus, by means of immunohistochemical staining of slices. Only a weak immunoreaction of these P450s was observed in astrocytes and oligodendrocytes. ImmunoGold electron microscopy revealed that P45017α and P450 aromatase were localized in pre- and postsynaptic compartments as well as in the endoplasmic reticulum in principal neurons. The expression of these cytochromes was further verified by using Western blot analysis and RT-PCR. Stimulation of hippocampal neurons with N-methyl-d-aspartate induced a significant net production of estradiol. Analysis of radioactive metabolites demonstrated the conversion from [3H]pregnenolone to [3H]estradiol through dehydroepiandrosterone and testosterone. This activity was abolished by the application of specific inhibitors of cytochrome P450s. Interestingly, estradiol was not significantly converted to other steroid metabolites. Taken together with our previous finding of a P450scc-containing neuronal system for pregnenolone synthesis, these results imply that 17β-estradiol is synthesized by P45017α and P450 aromatase localized in hippocampal neurons from endogenous cholesterol. This synthesis may be regulated by a glutamate-mediated synaptic communication that evokes Ca2+ signals.
The hippocampal formation, essentially involved in learning and memory processes, is known to be a target for the neuromodulatory actions of hormones produced in the gonads. As both estradiol and testosterone may reach the brain via blood circulation, and extensive studies have been performed to investigate their role in modulating hippocampal plasticity and function (1–4). Evidence is emerging that estrogen exerts not only the chronic/genomic effects but also a rapid/nongenomic influence on hippocampal synaptic plasticity (2, 5). In addition to endocrine-derived hormones, recent experiments have demonstrated that hippocampal neurons may also be exposed to locally synthesized brain neurosteroids, such as pregnenolone (PREG) and its sulfated ester (6–9). Dehydroepiandrosterone (DHEA) has been found in the mammalian brain at concentrations greater than that in plasma (6, 10). Because DHEA concentrations do not decrease after adrenalectomy and castration, many experiments have been performed with the aim of demonstrating the de novo synthesis of DHEA within the brain. DHEA biosynthesis has been demonstrated in cultured glial cells and neurons from the neonatal rat brain (11, 12). In the adult brain, however, a concrete demonstration of the synthesis of DHEA, androstenedione (AD), testosterone, or estradiol directly from endogenous cholesterol has yet to be reported. Sex steroids such as estradiol and testosterone, therefore, have not classically been considered to be “brain-derived neurosteroids.” Furthermore, the localization and activity of cytochrome P45017α (CYP17) in adult mammalian brain has also not been demonstrated, despite many sophisticated studies employing immunohistochemistry, molecular biology, and enzyme activity assays (13–16). P45017α has, therefore, been regarded to be only transiently expressed in the brain at embryonic and neonatal stages (11, 12, 14). Recently, a few studies have reported the presence of cytochrome P450 aromatase (P450arom, CYP19) in the adult rat and human hippocampal formation (17, 18).
The present study was designed to examine, in the adult male hippocampus, the cellular localization of P45017α and P450arom and the endogenous metabolism of neurosteroids from PREG. Analyses revealed the neuronal localization of these P450s and the synthesis of DHEA, testosterone, and 17β-estradiol, which suggests their intracrine/paracrine actions on the plasticity of neurons in adult rat brain.
Materials and Methods
Animals. Adult male Wistar rats (3 months old, 210–250 g) were purchased from SLC Japan and Harlan Sprague–Dawley. All experiments using animals in this study were conducted according to the institutional guidelines.
Immunohistochemical Staining of Hippocampal Slices. Immunohistochemical staining was performed essentially as described in refs. 7 and 8. The hippocampi were frozen-sliced with a cryostat. After application of either anti-P45017α IgG (19), at 1/1,000 dilution or anti-P450arom IgG (20) at 1/1,000, the slices were incubated for 18–36 h. Biotinylated anti-rabbit IgG and streptavidin–horseradish peroxidase complex (Vector Laboratories) was applied. Immunoreactive cells were detected in diaminobenzidine-nickel. Fluorescence immunohistochemistry was performed by using streptavidin–Oregon Green 488. For detailed description of the procedures, see Supporting Text, which is published as supporting information on the PNAS web site.
Postembedding ImmunoGold Method for Electron Microscopy. Hippocampal slices were prepared by using a vibratome. Freeze substitution and low-temperature embedding of the specimens was performed as described (21). Slices were plunged into liquid propane and immersed in uranyl acetate solution. After polymerization of Lowicryl HM20 resin, ultrathin sections (80 nm thickness) were cut by using an ultramicrotome. For immunolabeling, sections were incubated with primary antibody against P45017α (1:1,000) or P450arom (1:500) overnight and incubated with secondary gold-tagged (10 nm) Fab fragment in Tris-buffered saline. Sections were counterstained with 1% uranyl acetate and viewed on an electron microscope. For detailed description of the procedures, see Supporting Text.
Western Immunoblot Analysis. Microsomes were prepared as described in Supporting Text (8). After gel electrophoresis and the transfer to poly(vinylidene fluoride) membranes (Immobilon-P; Millipore), the blots were probed with antibodies against P45017α and P450arom at 1/5,000 dilution and incubated with biotinylated goat anti-rabbit IgG. The membranes were incubated with streptavidin–horseradish peroxidase complex. The protein bands were detected with ECL plus Western blotting detection reagents (Amersham Pharmacia).
RT-PCR and Southern Hybridization. The purified RNAs from rat tissues were reverse-transcribed by using a T-primed first-strand kit (Amersham Pharmacia) (22). Specific primer pairs and the PCR protocols are described in Supporting Text. For semiquantitative analysis (see ref. 23), the RT-PCR products were separated on 1.5% agarose gels, stained with ethidium bromide, and analyzed with a fluorescence gel scanner (Atto) and nih image software, in comparison with standard curves obtained from PCR of diluted reverse transcribed products (between 1/100 and 1/10,000 in dilution), from testis, ovary, or liver. The PCR products were cloned into TA-cloning vector (Promega) and sequenced. The resulting sequence was identical to the reported cDNA sequences. These cloned products were used as DNA probes for Southern hybridization. After transfer of the RT-PCR products to nylon membrane, Southern hybridization was performed with 32P-labeled cDNA probes for P45017α, P450arom, and GAPDH. Signals were measured by using a BAS-1000 Image analyzer (Fuji film).
HPLC Analysis. Procedures were essentially the same as described in ref. 8. Briefly, the hippocampal cubic slices were incubated with 5 × 106 cpm of [3H]steroids at 28°C in a 1.2 mM Mg2+ physiological saline (pH 7.2, consisting of 5 mM Hepes, etc.), into which 95% O2 gas was bubbled. [3H]steroids (DHEA, estradiol, etc.) were purchased from New England Nuclear, and their specific activities were 22.5–105 Ci/mmol (1 Ci = 37 GBq). After termination of the reaction, the slices were homogenized. To extract steroid metabolites, ethyl acetate/hexane (3:2) was applied to the homogenates. The organic phase was collected by centrifugation, dried, dissolved in an elution solvent of HPLC, and filtrated. The metabolites were separated by using an HPLC system (Jasco, Tokyo). For detailed description of the procedures, see Supporting Text.
RIA Analysis. Procedures were essentially the same as described in ref. 8. Briefly, plasma was prepared from trunk blood collected from decapitated rats. The hippocampal cubic slices were incubated at 37°C in 0.1mMMg2+ physiological saline into which O2 gas was bubbled. Extraction of steroids were performed as described in HPLC analysis. The estradiol or DHEA fractions were separated by using HPLC with solvent A, and reconstituted in a 0.1 M sodium phosphate buffer containing 0.1% gelatin. The concentration of steroids was measured by means of RIA, which was a competitive reaction assay, for example, between purified estradiol and exogenously added [3H]estradiol against estradiol IgG. Anti-steroid IgG was from ICN. For a detailed description of the procedures, see Supporting Text.
Results
Localization and Presence of Cytochrome P450s. Light microscopic investigations of the immunohistochemical staining were performed to determine the cell-specific localization of P45017α and P450arom in the hippocampal formation of adult male rats. Intense immunoreactions with anti-P45017α IgG (Fig. 1) and anti-P450arom IgG (Fig. 2) were restricted to pyramidal neurons in the CA1–CA3 regions and to granule cells in the dentate gyrus. The staining shows P45017α and P450arom to be distributed over the entire cell body, in general, and also along the dendrites of the pyramidal neurons in the CA3 region. Neurons were stained with IgG against neuronal nuclear antigen (NeuN). The colocalization of neurons with P45017α and P450arom was demonstrated by using fluorescence dual labeling procedures. Although the NeuN and P450 stainings were nearly superimposed, this was due to the localization of these cytochromes in the endoplasmic reticulum, distributed over the entire cell bodies, and thus did not indicate a nuclear localization of the cytochromes. Preadsorption of the antibody with an excess of purified guinea pig P45017α or human P450arom antigen (30 μg/ml) resulted in a complete disappearance of the immunoreactivity of these P450s, in all of the positively stained cells in the hippocampus.
The distribution of glial cells was investigated by the immunostaining of marker proteins. Antibodies against glial fibrillary acidic protein (GFAP) of astrocytes, stained star-shaped cells in the strata radiatum, and oriens in the hippocampus. IgG against myelin basic protein (MBP) of oligodendrocytes stained many long fibril cells in the hippocampus. Most of the cells stained with GFAP and MBP IgG were lacking in immunoreactivity to IgG against P45017α and P450arom. This indicates that most of the P45017α- and P450arom-containing cells are neither astrocytes nor oligodendrocytes.
The neuronal localization of P450 was further clarified by ultrastructural investigations. An immunoelectron microscopic analysis using postembedding immunogold was performed to determine the subcellular localization of P45017α and P450arom in hippocampal neurons of adult male rats. P45017α (Fig. 3A) and P450arom (Fig. 3B) were localized not only in the endoplasmic reticulum but also in both the axon terminals and dendritic spines of principal neurons. Gold particles were clustered in the endoplasmic reticulum of neurons. Gold particles were also localized within the presynaptic compartments, as well as within the postsynaptic compartments. In the presynaptic terminals, gold particles were primarily associated with synaptic vesicles. In dendrites, gold particles were distributed within the cytoplasm of the head of the spine. In some cases, gold particles were affiliated within the postsynaptic density. Preadsorption of the antibody with an excess of P45017α or P450arom antigen (30 μg/ml) resulted in a complete disappearance of the immunoreactivity of these P450s, in all of the positively stained cells.
There were essentially no significant differences between P45017α and P450arom concerning their topographical distribution in neurons. Investigations were performed mainly in the stratum radiatum of the CA1; however, the intraneuronal distribution of gold particles was essentially identical in the CA1, CA3, and dentate gyrus.
The presence of P45017α and P450arom proteins was verified by Western immunoblot analysis. In hippocampal microsomes, single protein bands were observed for P45017α and P450arom (Fig. 4). The concentration of P45017α and P450arom was ≈1/100th to 1/200th of that typical of the testis (P45017α) and ovary (P450arom). The electrophoretic mobility of the P45017α and P450arom bands indicated a molecular mass of ≈57 kDa and 58 kDa, respectively. These molecular masses were approximately equal to those in testis and ovary. Protein bands disappeared when either antibodies were preadsorbed with purified P450 antigens (30 μg/ml).
The level of mRNA transcripts for P45017α and P450arom was investigated by using RT-PCR analyses. The relative number of P450 transcripts expressed in the hippocampus (Fig. 5, lane 5) from adult male rats was demonstrated to be ≈1/200th to 1/300th of those expressed in the testis and ovary, for P45017α and P450arom, respectively. The mRNA levels for P45017α and P450arom in the hypothalamus (Fig. 5, lane 6) were slightly greater (by ≈1.5-fold) than those obtained in the hippocampus. On the other hand, the level of P45017α mRNA in the cerebral cortex (Fig. 5, lane 4) and cerebellum (Fig. 5, lane 7), was <10–4 and 10–3, respectively relative to levels observed in the testis. The level of P450arom mRNA, relative to levels in the ovary, was ≈1/500 in the cerebral cortex (Fig. 5, lane 4) and cerebellum (Fig. 5, lane 7).
The expression level of mRNA transcripts for 17β-hydroxysteroid dehydrogenase (17β-HSD) (types 1–4) was also investigated by using RT-PCR (data not shown). The level of 17β-HSD mRNA observed in the hippocampus was ≈1/10th relative to the level in the ovary for 17β-HSD (type 1), 1/200th to 1/300th relative to the level in the testis for 17β-HSD (type 3), roughly the same relative to the level in the liver for 17β-HSD (type 4), and <10–3 for 17β-HSD (type 2) relative to the level in the liver.
Steroid Metabolism Assay. The synthesis of estradiol in hippocampal slices was examined by means of a specific RIA using estradiol antibody (ICN) (Fig. 6). The basal concentration of estradiol observed in the hippocampus was 0.60 ± 0.05 fmol/mg wet weight (6.3 ± 0.5 fmol/mg protein; mean ± SEM from three independent experiments). The estradiol basal concentration in the plasma was 0.098 ± 0.039 fmol/μl (≈1.02 fmol/mg protein or 0.098 fmol/mg wet weight), a value considerably lower than that observed in the hippocampus. The N-methyl-d-aspartate (NMDA)-inducible production of estradiol was measured by stimulating hippocampal slices with 100 μM NMDA (Biomol) for 30 min, at 37°C in a 0.1 mM Mg2+ medium. This treatment increased the concentration of estradiol to 1.35 ± 0.18 fmol/mg wet weight (13.0 ± 1.7 fmol/mg protein), which is nearly twice the estradiol level in hippocampal slices incubated for 30 min without NMDA. Stimulation of net estradiol production with NMDA was completely suppressed by the application of 50 μM MK-801 (a specific blocker of NMDA receptors, Sigma). This enhancement in estradiol synthesis may be due to an increase in the NMDA receptor-mediated Ca2+ influx that drives the transport of cholesterol to the inner membrane of mitochondria, followed by a cascade of steroidogenesis (7). The basal concentration of DHEA was also measured in the hippocampus and plasma. The concentration of DHEA was 0.28 ± 0.07 fmol/mg wet weight (2.7 ± 0.7 fmol/mg protein) in the hippocampus, and 0.075 ± 0.036 fmol/μl in plasma. These values are in reasonable agreement with previous publications using DHEA extracts from the whole brain (6).
To analyze the pathway of steroidogenesis, the metabolism of radioactive steroids in hippocampal slices was investigated by using HPLC. To observe the conversion of PREG to DHEA, hippocampal cubic slices from adult male rats were incubated for 0, 1, 3, and 5 h at 28°C, using 5 × 106 cpm of [7-3H]PREG as a precursor. Careful attention was given to the removal of all fats from the hippocampal slices during the purification of steroids, before the application to HPLC. A portion of the purified radioactive metabolites (total of 106 cpm) was analyzed with an HPLC system, which used an elution liquid composed of hexane/isopropanol/acetic acid (97:3:1) (solvent A). The principal radioactive peak in the tritiated metabolite exhibited a retention time of ≈9.5 min, which was the same as that of [14C]DHEA used as a standard (Fig. 7A). A time-dependent increase in the [3H]DHEA fractions was observed over a period of 5 h (Fig. 8A, which is published as supporting information on the PNAS web site). Analysis of the steroid extract (adjusted to a total of 106 cpm) indicated that the amount of [3H]DHEA (product), relative to [3H]PREG (substrate), increased from 0.0 × 104/1.0 × 106 (0 h) to 1.0 × 104/0.98 × 106 (1 h), 2.9 × 104/0.97 × 106 (3 h), and 4.6 × 104/0.96 × 106 (5 h). Note that trilostane (Mochida) was included in these experiments to facilitate observation of the net production of [3H]DHEA by inhibiting 3β-hydroxysteroid dehydrogenase (3β-HSD). Trilostane prevents the conversion of DHEA to AD and of PREG to progesterone. The application of a specific inhibitor of P45017α, SU-10603 (Novartis) at 10 μM, reduced the production of [3H]DHEA to ≈21% of the control value. To exclude the possibility of contamination from other radioactive metabolites, the three fractions having a retention time of 9–10 min were combined and subjected to a second round of HPLC analysis. The column was eluted with a different elution solvent B (hexane/isopropanol/acetic acid = 98:2:1) for the normal phase HPLC (Fig. 8B), and with solvent C (acetonitrile/H2O = 40:60) for the reverse-phase HPLC (Fig. 7B), to improve the resolution. A single radioactive peak of [3H]metabolite having the same retention time as that of [14C]DHEA was observed in this second round of HPLC. These results indicate the significant enzymatic activity of P45017α in the hippocampus, which is responsible for the conversion of PREG to DHEA.
To investigate the conversion of DHEA to testosterone and estradiol, hippocampal slices were incubated with 5 × 106 cpm of [1,2,6,7-3H]DHEA for 5 h at 28°C, and the purified metabolites (total of 106 cpm) were analyzed by using HPLC. When elution solvent B was used, several eluent peaks were observed (Fig. 7C). The eluent peak with a retention time of 37 min was designated as testosterone by comparison with the standard [14C]testosterone. The eluent peak exhibiting a retention time of 21–22 min was close to the position of [14C]estradiol. To improve the resolution, these fractions were collected and subjected to a second round of HPLC analysis using solvent D (hexane/isopropanol/acetic acid = 99:1:1). A single peak, with a retention time of 51 min, was observed, which is in good agreement with [14C]estradiol (Fig. 8C). An additional round of analysis, using reverse-phase HPLC and solvent C, was performed for the HPLC fractions corresponding to estradiol, testosterone, and AD. These metabolites were again observed to elute at the same positions obtained for the standard [14C]steroids (Fig. 7D). Analysis of the steroid extract (106 cpm) indicated that the relative amount of [3H]estradiol (product) to [3H]DHEA (substrate) increased from 0.0 × 104/1.0 × 106 (0 h) to 3.5 × 104/0.90 × 106 (1 h), 5.5 × 104/0.88 × 106 (3 h) and 6.4 × 104/0.86 × 106 (5 h).
To confirm the participation of P450arom in estradiol synthesis, fadrozole (Novartis) was used to inhibit the activity of P450arom. A 30-min preincubation with 100 μM fadrozole, applied before the addition of [3H]DHEA, suppressed the conversion of [3H]DHEA to estradiol considerably (to ≈34% of the control), but had no suppressive effect on its conversion to testosterone (to ≈102% of the control) (Fig. 7C). The conversion from testosterone to estradiol and dihydrotestosterone (DHT) was then investigated. Hippocampal slices were incubated with [1,2,6,7-3H]testosterone (5 × 106 cpm) for 0, 1, 2, 3, 4, and 5 h at 28°C, and the purified metabolites (total of 106 cpm) were analyzed with HPLC using solvent B (Fig. 7E). A time-dependent increase in [3H]estradiol, [3H]DHT, and [3H]AD was observed (Fig. 8D). Analysis of the steroid extracts (106 cpm) indicted that the relative amount of [3H]estradiol (product) to [3H]testosterone (substrate) increased from 0.0 × 104/1.0 × 106 (0 h) to 0.7 × 104/0.90 × 106 (1 h), 1.9 × 104/0.87 × 106 (3 h) and 3.8 × 104/0.84 × 106 (5 h). The absence of other contaminating metabolites in these estradiol fractions was confirmed by means of a second round of HPLC using solvent C (for normal phase HPLC) and D (for reverse-phase HPLC).
HPLC analysis of AD and estrone metabolites are described in Supporting Text. Finally, the conversion of estradiol to other metabolites was also investigated by incubating [2,4,6,7-3H]estradiol (5 × 106 cpm) with hippocampal slices for 5 h. Only very small amounts of metabolites such as estrone and testosterone were observed (Fig. 7F), suggesting that estradiol was not significantly inactivated but may remain stable.
Discussion
Our results not only demonstrated the distribution of P45017α and P450arom in pyramidal and granule neurons at the light microscopic level (Figs. 1 and 2), but also indicated that these P450 proteins were specifically localized in pre- and post-synaptic locations and the endoplasmic reticulum of these neurons by electron microscopy, with a single molecule (gold particle) resolution (Fig. 3). These findings, combined with the results of steroid metabolism assays, strongly suggest that estradiol is endogenously synthesized in neurons from cholesterol in the hippocampal formation. These results indicate the need to reconsider the belief that these sex steroids are produced only in the gonads and reach the target brain via blood circulation. Rather, such steroids may be produced endogenously in the adult brain, where they play an essential role in the plasticity and protection of neurons.
Pathway of Steroidogenesis in the Hippocampus. In our previous work, the steroid synthesis was triggered by exposing neurons to NMDA, which induced a Ca2+ influx through the NMDA receptors and resulted in the significant production of PREG(s) (5, 7). A pool of full-length (37-kDa) steroidogenic acute regulatory protein (StAR) was processed to the truncated 30-kDa StAR upon NMDA stimulation (7). The expression of essential steroidogenic proteins [StAR, P450scc (CYP11A1), and 3β-HSD] in the hippocampal principal neurons was demonstrated by means of immunostaining and Western blot analysis (7–9) or by in situ hybridization (17, 22). The presence of mRNAs for 17β-HSD types 1–4 has been demonstrated in the human hippocampus (24). In the rat hippocampus, 17β-HSD (type 1) has been shown to be localized in neurons by immunostaining (25). Previous studies have shown the immunoreactivity of 5α-reductase in the rat hippocampus (16, 26).
In combination with these results, the current observations suggest that hippocampal neurons are equipped with a set of enzymes to catalyze the synthesis of estradiol from cholesterol. Neurosteroid synthesis may therefore proceed in the following manner. First, cholesterol is transported with StAR into the inner membrane of mitochondria, and converted to PREG by P450scc. After reaching the microsomes, P45017α converts PREG to DHEA. Then DHEA to AD by 3β-HSD, 17β-HSD (type 3) catalyzes the conversion of AD to testosterone. This is followed by a further transformation to estradiol by P450arom. It appears that estradiol is also formed by 17β-HSD (type 1) from estrone, which is converted from AD by P450arom.
The rate of production of steroid metabolites was rather low. The amount of [3H]DHEA formed from [3H]PREG, that of [3H]estradiol from [3H]DHEA, and that of [3H]estradiol from [3H]testosterone each represented ≈4.6–6.4% of the total radioactivity obtained by using [3H]steroid precursors, observed after 5-h incubation (Fig. 7). Several reasons are considered for this. First, the binding of exogenously applied [3H]steroid to P450s in hippocampal slices is likely to be very inefficient, as such steroids must penetrate deeply into cells in the thick slices to reach enzymes, without being absorbed by nonspecific binding to hydrophobic membranes, and replace endogenous steroid substrates already bound to the enzymes. Second, the conversion rate from [3H]PREG to [3H]DHEA by P45017α may indeed be extremely low; as a result, no previous study could detect this low activity. Third, not only [3H]DHEA but also other steroids such as sulfated DHEA and 7-hydroxyDHEA (27) may be produced in parallel from [3H]PREG. Fourth, [3H]estradiol is not a unique metabolite from [3H]testosterone, but DHT and other steroids may also be produced in parallel. These multiple pathways, including backward reactions, may be a primary reason of the observed low efficiency of steroid metabolism, because of the presence of sulfotransferase, 5α-reductase, and cytochrome P4507b (16, 26, 28). These factors could reduce the rate of production for [3H]DHEA and [3H]estradiol to 4.6–6.4% of the total radioactivity.
To verify that the observed low levels of radioactive metabolites were real products, we performed a set of control experiments. We observed a considerable decrease in [3H]DHEA production by the presence of SU-10603, inhibitor of P45017α (Fig. 7A). In addition, estradiol production was suppressed considerably by the presence of fadrozole, an inhibitor of P450arom (Fig. 7C). These results indicate that the observed steroid metabolite levels are above the detection limit of the HPLC analysis. The background radioactivity in the HPLC profiles in Fig. 7 was <300 cpm at any position, using hippocampal slices fixed with paraformaldehyde to inactivate steroidogenic enzymes before incubation with 3H-substrate steroids.
Glial cells have been considered to play an important role in neurosteroidogenesis, as many reports have indicated the presence of mRNA and steroidogenic activity for P450scc, P45017α, 3β-HSD, and 17β-HSD in cultures of astrocytes and oligodendrocytes (6, 11, 12, 29, 30). Based on these studies, the following steroidogenic sequence is suggested in the neonatal rat brain. The primary source of PREG is the oligodendrocytes. PREG is then transferred to the astrocytes, where it is converted to DHEA, and further metabolized to sex steroids (11, 12). It should be noted, however, that these studies, which use primary glial cell cultures, can be performed only for embryonic and neonatal brain. As a result, direct information is not available from these studies regarding the biosynthesis of neurosteroids in adult rat brain. The possibility of glial steroidogenesis in the adult hippocampal formation cannot be excluded by the present study, as a weak staining of P450scc (7), P45017α, and P450arom was observed in some glia-like cells.
Previous Understanding of P45017α and P450arom in the Brain. A direct demonstration of the neuronal synthesis of DHEA in adult mammalian brain has not previously been reported, although the presence of significant amounts of DHEA had been noted (15, 10). It has therefore been assumed that DHEA and the sex steroids are supplied to the brain via the blood circulation (6, 15, 20). As reported in a number of studies, the absence of P45017α and its activity in the brain of adult mammals has discouraged the investigation of the endogenous synthesis of sex steroids and DHEA in adult brain (13–16). Incubations of [3H]PREG with brain slices and microsomes from rat and mouse, had failed to produce [3H]DHEA (15). Moreover, many attempts to demonstrate the immunohistochemical reactivity for P45017α in the rat brain had been unsuccessful (13). mRNAs for P45017α had not been detected in adult rat brain by either RNase protection assays or RT-PCR (14). The expression of the mRNA for P45017α had been reported by many laboratories as only transient, occurring during rat embryonic and neonatal development (11, 12, 31). Although a similar level of P45017α mRNA had been reported in both astrocytes and neurons in primary cultures from the brain of neonatal rats, neurons had exhibited a much lower metabolic activity than astrocytes for the conversion of PREG to DHEA (11, 12). Such investigations, which use primary cell cultures, are not possible for adult brains, because cells from adult brains cannot be cell cultured.
Our observation of a significant amount of P45017α mRNA was achieved due to (i) a careful design of primers to not include sequences that may form stable loops, inhibiting binding to mRNA, (ii) the use of isolated rat hippocampal formation, rather than brain mixtures where the cortex did not express P45017α mRNA, and (iii) the considerable improvement in the last few years of the commercially available enzymes such as Taq polymerase used for RT-PCR.
The role of P450arom in the hippocampus had also not been well elucidated, primarily because many studies had indicated the absence of P450arom in the adult rat and mouse hippocampus (20, 32). Recently, however, the significant expression of mRNA for P450arom in the pyramidal and granule neurons of the adult rat hippocampus has been demonstrated by using in situ hybridization (17). The level of the mRNA expression in the adult mouse hippocampus was approximately half of that in neonatal stages (23). The activity of P450arom has been suggested in the adult male rat hippocampus based on the results of the testosterone-induced protection of the hippocampal neuronal death induced by the domoic acid-treatments (3).
Modulation by Estradiol of Hippocampal Neurons. Investigations have been focused on female rats regarding the chronic, delayed effects of estradiol on synaptic plasticity. For example, the dendritic spine density in pyramidal neurons is sensitive to the estrous cycle (1, 33) and also to experimentally induced estrogen depletion and replacement, which serve to modulate estrogen levels in blood circulation (4). Estradiol also induces rapid effects. A 20-min preperfusion of 1–10 nM estradiol induced the rapid modulation of long-term potentiation of the CA1 neurons in the hippocampal slices (2). Our elucidation of the estradiol-synthesis in principal neurons, which begins with cholesterol, introduces an essentially a new supply of brain neurosteroids, in addition to gonads. Estradiol synthesis may be dependent on NMDA receptor-mediated Ca2+ influx, thereby dependent on synaptic communication (5, 7). The concentration of endogenously synthesized estradiol by NMDA stimulation (≈0.75 nM; see Fig. 6, column 3) should be sufficient to modulate these neuronal activities, because the local concentration of estradiol (at the site of synthesis) may transiently be an order of magnitude higher than the mean concentration of 0.75 nM.
Supplementary Material
Acknowledgments
We thank Dr. J. Rose for critical reading of the manuscript. We thank Novartis for the kind gift of SU-10603. This work was supported in part by National Institutes of Health Grant PO1AG16765 (to J.H.M.).
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: PREG, pregnenolone; DHEA, dehydroepiandrosterone; AD, androstenedione; P450arom, cytochrome P450 aromatase; 17β-HSD, 17β-hydroxysteroid dehydrogenase; DHT, dihydrotestosterone.
References
- 1.Woolley, C. S., Weiland, N. G., McEwen, B. S. & Schwartzkroin, P. A. (1997) J. Neurosci. 17, 1848–1859. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Foy, M. R. Xu, J. Xie, X. Brinton, R. D. Thompson, R. F. & Berger, T. W. (1999) J. Neurophisiol. 81, 925–929. [DOI] [PubMed] [Google Scholar]
- 3.Azcoitia, I., Sierra, A., Veiga, S., Honda, S., Harada, N. & Garcia-Segura, L. M. (2001) J. Neurobiol. 47, 318–329. [DOI] [PubMed] [Google Scholar]
- 4.Pozzo-Miller, L. D., Inoue, T. & Murphy, D. D. (1999) J. Neurophysiol. 81, 1404–1411. [DOI] [PubMed] [Google Scholar]
- 5.Shibuya, K., Takata, N., Hojo, Y., Furukawa, A., Yasumatsu, N., Kimoto, T., Enami, T., Suzuki, K., Tanabe, N., Ishii, H., et al. (2002) Biochim. Biophys. Acta 25462, 1–16. [DOI] [PubMed] [Google Scholar]
- 6.Baulieu, E. E. (1997) Recent Prog. Horm. Res. 52, 1–32. [PubMed] [Google Scholar]
- 7.Kimoto, T., Tsurugizawa, T., Ohta, Y., Makino, J., Tamura, H., Hojo, Y., Takata, N. & Kawato, S. (2001) Endocrinology 142, 3578–3589. [DOI] [PubMed] [Google Scholar]
- 8.Kawato, S., Hojo, Y. & Kimoto, T. (2002) Methods Enzymol. 357, 241–249. [DOI] [PubMed] [Google Scholar]
- 9.Kawato, S., Yamada, M. & Kimoto, T. (2003) Adv. Biophys. 37, 1–48. [DOI] [PubMed] [Google Scholar]
- 10.Corpechot, C., Robel, P., Axelson, M., Sjovall, J. & Baulieu, E. E. (1981) Proc. Natl. Acad. Sci. USA 78, 4704–4707. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Zwain, I. H. & Yen, S. S. C. (1999) Endocrinology 140, 880–887. [DOI] [PubMed] [Google Scholar]
- 12.Zwain, I. H. & Yen, S. S. C. (1999) Endocrinology 140, 3843–3852. [DOI] [PubMed] [Google Scholar]
- 13.Le Goascogne, C., Sananes, N., Gouezou, M., Takemori, S., Kominami, S., Baulieu, E. E. & Robel, P. (1991) J. Reprod. Fertil. 93, 609–622. [DOI] [PubMed] [Google Scholar]
- 14.Mellon, S. H. & Deschepper, C. F. (1993) Brain Res. 629, 283–292. [DOI] [PubMed] [Google Scholar]
- 15.Baulieu, E. E. & Robel, P. (1998) Proc. Natl. Acad. Sci. USA 95, 4089–4091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Mensah-Nyagan, A. G., Do-Rego, J. L., Beaujean, D., Luu-The, V., Pelletier, G. & Vaudry, H. (1999) Pharm. Rev. 51, 63–81. [PubMed] [Google Scholar]
- 17.Wehrenberg, U., Prange-Kiel, J. & Rune, G. M. (2001) J. Neurochem. 76, 1879–1886. [DOI] [PubMed] [Google Scholar]
- 18.Stoffel-Wagner, B., Watzka, M., Schramm, J., Bidlingmaier, F. & Klingmuller, D. (1999) J. Steroid Biochem. Mol. Biol. 70, 237–241. [DOI] [PubMed] [Google Scholar]
- 19.Shinzawa, K., Ishibashi, S., Murakoshi, M., Watanabe, K., Kominami, S., Kawahara, A. & Takemori, S. (1988) J. Endocrinol. 119, 191–200. [DOI] [PubMed] [Google Scholar]
- 20.Jakab, R. L., Horvath, T. L., Leranth, C., Harada, N. & Naftolin, F. (1993) J. Steroid Biochem. Mol. Biol. 44, 481–498. [DOI] [PubMed] [Google Scholar]
- 21.Adams, M. M., Shah, R. A., Janssen, W. G. M. & Morrison, J. H. (2001) Proc. Nat. Acad. Sci. USA, 98, 8071–8076. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Furukawa, A., Miyatake, A., Ohnishi, T. & Ichikawa, Y. (1998) J. Neurochem. 71, 2231–2238. [DOI] [PubMed] [Google Scholar]
- 23.Ivanova, T. & Beyer, C., (2000) Cell Tissue Res. 300, 231–237. [DOI] [PubMed] [Google Scholar]
- 24.Beyenburg, S., Watzka, M., Blumcke, I., Schramm, J., Bidlingmaier, F., Elger, C. E. & Stoffel-Wagner, B. (2000) Epilepsy Res. 41, 83–91. [DOI] [PubMed] [Google Scholar]
- 25.Pelletier, G., Luu-The, V. & Labrie, F. (1995) Brain Res. 704, 233–239. [DOI] [PubMed] [Google Scholar]
- 26.Melcangi, R. C., Cellotti, P., Castano, P. & Martini, L. (1993) Endocrinology 132, 1252–1259. [DOI] [PubMed] [Google Scholar]
- 27.Jellinck, P., Lee, S. J. & McEwen, B S., (2001) Steroid Biochem. Mol. Biol. 78, 313–317. [DOI] [PubMed] [Google Scholar]
- 28.Rose, K., Stapleton, G., Dott, K., Kieny, M. P., Best, R., Schwarz, M., Russel, D. W., Bjorkhem, I., Seckl, J. & Lathe, R. (1997) Proc. Natl. Acad. Sci. USA 94, 4925–4930. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Jung-Testas, I., Hu, Z. Y., Baulieu, E. E. & Robel, P. (1989) Endocrinology 125, 2083–2091. [DOI] [PubMed] [Google Scholar]
- 30.Papadopoulos, V. (1993) Endocr. Rev. 14, 222–240. [DOI] [PubMed] [Google Scholar]
- 31.Compagnone, N. A., Bulfone, A., Rubenstein, J. L. R. & Mellon, S. H. (1995) Endocrinology 136, 5212–5223. [DOI] [PubMed] [Google Scholar]
- 32.Lauber, M. E. & Lichtensteiger, W. (1994) Endocrinology 135, 1611–1668. [DOI] [PubMed] [Google Scholar]
- 33.Woolley, C. S. & McEwen, B. S. (1994) J. Neurosci. 14, 7680–7687. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.